Last reviewed · How we verify
Blink tears
Blink Tears is an artificial tear solution that lubricates and moisturizes the ocular surface to relieve dry eye symptoms.
Blink Tears is an artificial tear solution that lubricates and moisturizes the ocular surface to relieve dry eye symptoms. Used for Dry eye syndrome / Keratoconjunctivitis sicca, Temporary relief of burning and irritation due to dry eyes.
At a glance
| Generic name | Blink tears |
|---|---|
| Sponsor | Medical University of South Carolina |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This over-the-counter ophthalmic lubricant mimics natural tear composition to provide temporary relief of dry eye discomfort. It works by coating the cornea and conjunctiva with a protective film that reduces evaporation of natural tears and provides moisture to the ocular surface.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Temporary relief of burning and irritation due to dry eyes
Common side effects
- Transient blurred vision
- Eye irritation
- Allergic reaction (rare)
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body (PHASE1)
- The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation (NA)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery (PHASE4)
- Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |